Operator: Your next question comes from the line of Brandon Folkes from Cantor Fitzgerald. Your line is open.
Brandon Folkes: Hi. Thanks for taking my questions and congratulations on all the progress. Just a very high level one from me. Maybe, can you help us just conceptualize or think about where you are in terms of, sort of the strategy? And what I mean by that is, obviously tremendous progress in 2022, looks like continued significant progress in 2023 based on the guidance, but sort of how much opportunity do you see to continue on the, sort of growing concentrate and, kind of optimizing the cost structure within the next few years? How should we think about that versus maybe, sort of evolving the strategy over the next few years? Thank you.
Mark Strobeck: Yes. Thanks Brandon. So, as we’ve discussed previously, the goal and we see a path to building this business to a $100 million plus in revenue. And we think we have a path that allows us to do that. We’ve also spoken to the fact that we want to become €“ our primary objective is to become the leading supplier of hemodialysis concentrates worldwide. And so, again, further growth for us will include tapping into international markets where we do not currently provide products today. And so, that’s where the additional growth will come from. And then I think third to that, for the first time now being outside of the Baxter agreement, we have the ability to contemplate adding new products to our portfolio. And so, we are actively evaluating additional products to add that take advantage of our manufacturing capacity and expertise, as well as our distribution capabilities to grow out a larger renal care portfolio.
So, those are some of the areas that I would say that we are focused on to growing this business, sort of well beyond where we stand today.
Brandon Folkes: Great. Thank you very much and congratulations on all the progress.
Mark Strobeck: Thanks, Brandon.
Operator: And there are no further questions. I will now turn the call back over to Dr. Strobeck.
Mark Strobeck: Thank you, operator, and thank you everyone for joining us on today’s call. It was a pleasure to provide you with an overview of our accomplishments in 2022. We are steadfast and focused on driving our overall business to profitability, improving our financial position, maximizing revenue, and unlocking the value of our manufacturing and distribution capabilities. We are putting Rockwell Medical in a better position to drive growth and further improve our performance so we can serve more patients, clinics, and major medical centers around the world. We are in the business to make products that impact the patient’s life. This is our passion and we take this responsibility very seriously. We look forward to sharing our progress on future calls.
Operator: This concludes today’s conference call and webcast. You may now disconnect.
